PURPOSE: Single-fraction image-guided intensity-modulated radiation therapy (IG-IMRT) allows for tumoricidal treatment of traditionally radioresistant cancers while sparing critical adjacent structures. Risk of vertebral fracture after IG-IMRT for spinal metastases has not been defined. PATIENTS AND METHODS: We evaluated 62 consecutive patients undergoing single fraction IG-IMRT at 71 sites for solid organ metastases. A neuroradiologist and three spine surgeons evaluated prospectively obtained magnetic resonance/computed tomography (CT) imaging studies for post-treatment fracture development and tumor recurrence. RESULTS: Fracture progression was noted in 27 vertebrae (39%). Multivariate logistic regression analysis showed that CT appearance, lesion location, and percent vertebral body involvement independently predicted fracture progression. Lesions located between T10 and the sacrum were 4.6 times more likely to fracture than were lesions above T10 (95% CI, 1.1 to 19.7). Lytic lesions were 6.8 times more likely to fracture than were sclerotic and mixed lesions (95% CI, 1.4 to 33.3). As percent vertebral body involvement increased, odds of fracture also increased. Patients with fracture progression had significantly higher narcotic use, change in Karnofsky performance score, and a strong trend toward higher pain scores. Local tumor progression occurred in seven patients and contributed to one fracture. Obesity, posterior element involvement, bisphosphonate use, and local kyphosis did not confer increased risk. CONCLUSION: Vertebral fracture is common after single fraction IG-IMRT for metastatic spine lesions. Lytic disease involving more than 40% of the vertebral body and location at or below T10 confer a high risk of fracture, the presence of which yields significantly poorer clinical outcomes. These results may help clinicians identify high-risk patients who would benefit from prophylactic vertebro- or kyphoplasty.
PURPOSE: Single-fraction image-guided intensity-modulated radiation therapy (IG-IMRT) allows for tumoricidal treatment of traditionally radioresistant cancers while sparing critical adjacent structures. Risk of vertebral fracture after IG-IMRT for spinal metastases has not been defined. PATIENTS AND METHODS: We evaluated 62 consecutive patients undergoing single fraction IG-IMRT at 71 sites for solid organ metastases. A neuroradiologist and three spine surgeons evaluated prospectively obtained magnetic resonance/computed tomography (CT) imaging studies for post-treatment fracture development and tumor recurrence. RESULTS:Fracture progression was noted in 27 vertebrae (39%). Multivariate logistic regression analysis showed that CT appearance, lesion location, and percent vertebral body involvement independently predicted fracture progression. Lesions located between T10 and the sacrum were 4.6 times more likely to fracture than were lesions above T10 (95% CI, 1.1 to 19.7). Lytic lesions were 6.8 times more likely to fracture than were sclerotic and mixed lesions (95% CI, 1.4 to 33.3). As percent vertebral body involvement increased, odds of fracture also increased. Patients with fracture progression had significantly higher narcotic use, change in Karnofsky performance score, and a strong trend toward higher pain scores. Local tumor progression occurred in seven patients and contributed to one fracture. Obesity, posterior element involvement, bisphosphonate use, and local kyphosis did not confer increased risk. CONCLUSION:Vertebral fracture is common after single fraction IG-IMRT for metastatic spine lesions. Lytic disease involving more than 40% of the vertebral body and location at or below T10 confer a high risk of fracture, the presence of which yields significantly poorer clinical outcomes. These results may help clinicians identify high-risk patients who would benefit from prophylactic vertebro- or kyphoplasty.
Authors: Yoshiya Yamada; Mark H Bilsky; D Michael Lovelock; Ennapadam S Venkatraman; Sean Toner; Jared Johnson; Joan Zatcky; Michael J Zelefsky; Zvi Fuks Journal: Int J Radiat Oncol Biol Phys Date: 2008-01-30 Impact factor: 7.038
Authors: F M Maynard; M B Bracken; G Creasey; J F Ditunno; W H Donovan; T B Ducker; S L Garber; R J Marino; S L Stover; C H Tator; R L Waters; J E Wilberger; W Young Journal: Spinal Cord Date: 1997-05 Impact factor: 2.772
Authors: S M Pierce; A Recht; T I Lingos; A Abner; F Vicini; B Silver; A Herzog; J R Harris Journal: Int J Radiat Oncol Biol Phys Date: 1992 Impact factor: 7.038
Authors: Adam N Wallace; Ross Vyhmeister; Andy C Hsi; Clifford G Robinson; Randy O Chang; Jack W Jennings Journal: Interv Neuroradiol Date: 2015-10-23 Impact factor: 1.610
Authors: Michael Farris; Emory R McTyre; Catherine Okoukoni; Greg Dugan; Brendan J Johnson; A William Blackstock; Michael T Munley; J Daniel Bourland; J Mark Cline; Jeffrey S Willey Journal: Radiat Res Date: 2018-05-08 Impact factor: 2.841
Authors: Daniel Lubelski; Joseph E Tanenbaum; Taylor E Purvis; Thomas T Bomberger; Courtney Rory Goodwin; Ilya Laufer; Daniel M Sciubba Journal: CNS Oncol Date: 2017-07-18
Authors: Yoshiya Yamada; Evangelia Katsoulakis; Ilya Laufer; Michael Lovelock; Ori Barzilai; Lily A McLaughlin; Zhigang Zhang; Adam M Schmitt; Daniel S Higginson; Eric Lis; Michael J Zelefsky; James Mechalakos; Mark H Bilsky Journal: Neurosurg Focus Date: 2017-01 Impact factor: 4.047